The estimated Net Worth of Glen C Mac Donald is at least $808 mil dollars as of 2 March 2023. Dr Donald owns over 286,292 units of Sesen Bio stock worth over $272,668 and over the last 5 years he sold SESN stock worth over $15,297. In addition, he makes $519,698 as Chief Technology Officer at Sesen Bio.
Dr has made over 2 trades of the Sesen Bio stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 286,292 units of SESN stock worth $168,912 on 2 March 2023.
The largest trade he's ever made was exercising 286,292 units of Sesen Bio stock on 2 March 2023 worth over $168,912. On average, Dr trades about 52,037 units every 2 days since 2019. As of 2 March 2023 he still owns at least 432,806 units of Sesen Bio stock.
You can see the complete history of Dr Donald stock trades at the bottom of the page.
Dr. Glen C. MacDonald is the Chief Technology Officer at Sesen Bio.
As the Chief Technology Officer of Sesen Bio, the total compensation of Dr MacDonald at Sesen Bio is $519,698. There are 5 executives at Sesen Bio getting paid more, with Thomas Cannell having the highest compensation of $1,404,240.
Dr MacDonald is 70, he's been the Chief Technology Officer of Sesen Bio since . There are no older and 16 younger executives at Sesen Bio.
Glen's mailing address filed with the SEC is C/O SESEN BIO, INC., SUITE 1800, CAMBRIDGE, MA, 02142.
Over the last 6 years, insiders at Sesen Bio have traded over $121,419 worth of Sesen Bio stock. The most active insiders traders include Thomas R Cannell, Monica Forbes y Mark Sullivan. On average, Sesen Bio executives and independent directors trade stock every 1 days with the average trade being worth of $111,396. The most recent stock trade was executed by Mark Sullivan on 2 March 2023, trading 298,175 units of SESN stock currently worth $175,923.
Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company's lead program, Vicineum™, also known as VB4-845, is currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In December 2020, the Company completed the BLA submission for Vicineum to the FDA. Sesen Bio retains worldwide rights to Vicineum with the exception of Greater China and the Middle East and North Africa (MENA), for which the Company has partnered with Qilu Pharmaceutical and Hikma Pharmaceuticals, respectively, for commercialization. Vicineum is a locally administered targeted fusion protein composed of an anti-EpCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A for the treatment of high-risk NMIBC.
Sesen Bio executives and other stock owners filed with the SEC include: